AYTU Key Statistics, Chart & Performance
The current stock price of AYTU is 2.45 USD. In the past month the price increased by 16.67%. In the past year, price increased by 61.18%.
AYTU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.01 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.24B | ||
| MRK | MERCK & CO. INC. | 12.12 | 265.03B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.23B | ||
| ZTS | ZOETIS INC | 19.91 | 55.63B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.64B | ||
| VTRS | VIATRIS INC | 5.29 | 14.19B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.54 | 11.23B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.92 | 8.69B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About AYTU
Company Profile
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Company Info
AYTU BIOPHARMA INC
7900 E. Union Avenue, Suite 920
Denver COLORADO 80112 US
CEO: Joshua R. Disbrow
Employees: 82
Phone: 17204376580
AYTU BIOPHARMA INC / AYTU FAQ
Can you describe the business of AYTU BIOPHARMA INC?
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
What is the stock price of AYTU BIOPHARMA INC today?
The current stock price of AYTU is 2.45 USD. The price decreased by -3.16% in the last trading session.
What is the dividend status of AYTU BIOPHARMA INC?
AYTU does not pay a dividend.
How is the ChartMill rating for AYTU BIOPHARMA INC?
AYTU has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is AYTU stock listed?
AYTU stock is listed on the Nasdaq exchange.
How is the valuation of AYTU BIOPHARMA INC (AYTU) based on its PE ratio?
AYTU BIOPHARMA INC (AYTU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.76).
What is the expected growth for AYTU stock?
The Revenue of AYTU BIOPHARMA INC (AYTU) is expected to decline by -20.09% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AYTU Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AYTU. When comparing the yearly performance of all stocks, AYTU is one of the better performing stocks in the market, outperforming 93.43% of all stocks.
AYTU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYTU. AYTU may be in some trouble as it scores bad on both profitability and health.
AYTU Financial Highlights
Over the last trailing twelve months AYTU reported a non-GAAP Earnings per Share(EPS) of -2.76. The EPS decreased by -193.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.46% | ||
| ROE | -56.41% | ||
| Debt/Equity | 1.09 |
AYTU Forecast & Estimates
9 analysts have analysed AYTU and the average price target is 9.52 USD. This implies a price increase of 288.57% is expected in the next year compared to the current price of 2.45.
For the next year, analysts expect an EPS growth of 54.04% and a revenue growth -20.09% for AYTU